期刊
EPIGENOMICS
卷 11, 期 13, 页码 1539-1552出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2019-0090
关键词
cancer epigenetics; HOX genes; DNA methylation; DNA methyltransferase; epigenetic gene regulation; epigenetic therapies; therapeutic targets
资金
- North Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
- European Regional Development Fund (ERDF) through the COMPETE - Operational Competitiveness Programme [NORTE-01-0145-FEDER-000029]
- European Regional Development Fund (ERDF) through POPH - Operational Human Potential Programme [NORTE-01-0145-FEDER-000029]
- national funds through FCT - Foundation for Science and Technology [POCI01-0145-FEDER-030562]
Several HOX genes are aberrantly expressed in a wide range of cancers interfering with their development and resistance to treatment. This seems to be often caused by alterations in the methylation profiles of their promoters. The role of HOX gene products in cancer is highly 'tissue specific', relying ultimately on their ability to regulate oncogenes or tumor-suppressor genes, directly as transcriptional regulators or indirectly interfering with the levels of epigenetic regulators. Nowadays, different strategies have been tested the use of HOX genes as therapeutic targets for cancer diagnosis and treatment. Here, we trace the history of the research concerning the involvement of HOX genes in cancer, their connection with epigenetic regulation and their potential use as therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据